These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 21566577)

  • 21. B-Raf kinase inhibitors for cancer treatment.
    Li N; Batt D; Warmuth M
    Curr Opin Investig Drugs; 2007 Jun; 8(6):452-6. PubMed ID: 17621874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted Therapy for Melanoma.
    Wong DJ; Ribas A
    Cancer Treat Res; 2016; 167():251-62. PubMed ID: 26601866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting mutant BRAF and KIT in metastatic melanoma: ASCO 2009 meeting report.
    Sondak VK; Smalley K
    Pigment Cell Melanoma Res; 2009 Aug; 22(4):386-7. PubMed ID: 19624312
    [No Abstract]   [Full Text] [Related]  

  • 24. [Dabrafenib: the new inhibitor of hyperactive B-RAF kinase].
    Heneberg P
    Klin Onkol; 2012; 25(5):333-9. PubMed ID: 23102194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of the PI3K-AKT pathway in melanoma.
    Davies MA
    Cancer J; 2012; 18(2):142-7. PubMed ID: 22453015
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential sensitivity of melanoma cell lines with differing B-Raf mutational status to the new oncogenic B-Raf kinase inhibitor UI-152.
    Kim YK; Ahn SK; Lee M
    Cancer Lett; 2012 Jul; 320(2):215-24. PubMed ID: 22425959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor.
    Seghers AC; Wilgenhof S; Lebbé C; Neyns B
    Melanoma Res; 2012 Dec; 22(6):466-72. PubMed ID: 22584957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.
    Sharma A; Trivedi NR; Zimmerman MA; Tuveson DA; Smith CD; Robertson GP
    Cancer Res; 2005 Mar; 65(6):2412-21. PubMed ID: 15781657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Meeting report from the 2011 International Melanoma Congress, Tampa, Florida.
    Smalley KS; Aplin AE; Flaherty KT; Hoeller C; Bosserhoff AK; Haass NK; Bosenberg M; Ribas A; Barnhill R; Kudchadkar R; Messina JL
    Pigment Cell Melanoma Res; 2012 Jan; 25(1):E1-11. PubMed ID: 22117673
    [No Abstract]   [Full Text] [Related]  

  • 30. Targeted therapies in gynecologic cancers and melanoma.
    Ortega E; Marti RM; Yeramian A; Sorolla A; Dolcet X; Llobet D; Abal L; Santacana M; Pallares J; Llombart-Cussac A; Matias-Guiu X
    Semin Diagn Pathol; 2008 Nov; 25(4):262-73. PubMed ID: 19013892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Natural products as antitumor agents: direct versus indirect mechanisms of activity of flavonoids.
    Wiltrout RH; Hornung RL
    J Natl Cancer Inst; 1988 Apr; 80(4):220-2. PubMed ID: 3351957
    [No Abstract]   [Full Text] [Related]  

  • 32. Perturbing resistance: a network perspective.
    Levesque MP; Dummer R; Beerenwinkel N
    Pigment Cell Melanoma Res; 2016 Jan; 29(1):5-7. PubMed ID: 26471867
    [No Abstract]   [Full Text] [Related]  

  • 33. Predicting anti-cancer activity in flavonoids: a graph theoretic approach.
    Mukwembi S; Nyabadza F
    Sci Rep; 2023 Feb; 13(1):3309. PubMed ID: 36849585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is resistance to targeted therapy in cancer inevitable?
    Smith LK; Sheppard KE; McArthur GA
    Cancer Cell; 2021 Aug; 39(8):1047-1049. PubMed ID: 34375607
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Parr et al. Respond to "Recall Bias in Melanoma".
    Parr CL; Hjartåker A; Laake P; Lund E; Veierød MB
    Am J Epidemiol; 2009 Feb; 169(3):271-272. PubMed ID: 19011115
    [No Abstract]   [Full Text] [Related]  

  • 36. Targeted therapies: In melanoma, resistance is futile?
    Kirk R
    Nat Rev Clin Oncol; 2011 May; 8(5):253. PubMed ID: 21468134
    [No Abstract]   [Full Text] [Related]  

  • 37. Solid-state studies and antioxidant properties of the γ-cyclodextrin·fisetin inclusion compound.
    Pais JM; Barroca MJ; Marques MPM; Almeida Paz FA; Braga SS
    Beilstein J Org Chem; 2017; 13():2138-2145. PubMed ID: 29062435
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting drivers of melanoma with synthetic small molecules and phytochemicals.
    Strickland LR; Pal HC; Elmets CA; Afaq F
    Cancer Lett; 2015 Apr; 359(1):20-35. PubMed ID: 25597784
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fisetin: a dietary antioxidant for health promotion.
    Khan N; Syed DN; Ahmad N; Mukhtar H
    Antioxid Redox Signal; 2013 Jul; 19(2):151-62. PubMed ID: 23121441
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.